Search for Clinical Trial Results
Mucopolysaccharidosis I - 101 Studies Found
Status | Study |
Active, not recruiting |
Study Name: Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I Condition: Mucopolysaccharidosis I Date: 2015-02-19 Interventions: Drug: AGT-181 (HIRMAb-IDUA) intravenous infusion over 3-4 hours |
Enrolling by invitation |
Study Name: Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I Condition: Date: 2024-05-02 |
Active, not recruiting |
Study Name: Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I Condition: Mucopolysaccharidosis I Date: 2017-02-09 Interventions: Drug: AGT-181 Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion |
Recruiting |
Study Name: Mucopolysaccharidosis I (MPS I) Registry Condition: Mucopolysaccharidosis I (MPS I) Date: 2005-09-02 |
Completed |
Study Name: Immune Tolerance Study With Aldurazyme® (Laronidase) Condition: Mucopolysaccharidosis I Date: 2008-08-13 Interventions:
|
Enrolling by invitation |
Study Name: Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in MPS I Condition:
Date: 2014-09-03 Interventions: Drug: Intrathecal recombinant human alpha iduronidase Intrathecal recombinant human alpha iduronidase ev |
Completed |
Study Name: Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease Condition:
Date: 2017-05-11 Interventions:
|
Recruiting |
Study Name: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I Condition: MPS I Date: 2016-02-29 Interventions: Biological: SB-318 A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, |
Completed |
Study Name: Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients Condition:
|